These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15501786)

  • 1. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.
    Arnold H; Bumann D; Felies M; Gewecke B; Sörensen M; Gessner JE; Freihorst J; von Specht BU; Baumann U
    Infect Immun; 2004 Nov; 72(11):6546-53. PubMed ID: 15501786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
    Baumann U; Göcke K; Gewecke B; Freihorst J; von Specht BU
    Respir Res; 2007 Aug; 8(1):57. PubMed ID: 17683588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
    Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
    Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.
    Bumann D; Behre C; Behre K; Herz S; Gewecke B; Gessner JE; von Specht BU; Baumann U
    Vaccine; 2010 Jan; 28(3):707-13. PubMed ID: 19887136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.
    Göcke K; Baumann U; Hagemann H; Gabelsberger J; Hahn H; Freihorst J; von Specht BU
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):167-71. PubMed ID: 12832121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
    Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
    Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
    J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
    Mansouri E; Blome-Eberwein S; Gabelsberger J; Germann G; von Specht BU
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):161-6. PubMed ID: 12832120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.
    Baumann U; Mansouri E; von Specht BU
    Vaccine; 2004 Feb; 22(7):840-7. PubMed ID: 15040936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
    Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
    Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal and systemic immune responses to chimeric fimbriae expressed by Salmonella enterica serovar typhimurium vaccine strains.
    Chen H; Schifferli DM
    Infect Immun; 2000 Jun; 68(6):3129-39. PubMed ID: 10816454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.
    DiGiandomenico A; Rao J; Goldberg JB
    Infect Immun; 2004 Dec; 72(12):7012-21. PubMed ID: 15557624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral immunization using HgbA in a recombinant chancroid vaccine delivered by attenuated Salmonella typhimurium SL3261 in the temperature-dependent rabbit model.
    Breau C; Cameron DW; Desjardins M; Lee BC
    J Immunol Methods; 2012 Jan; 375(1-2):232-42. PubMed ID: 22100216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of oral immunization with attenuated Salmonella typhimurium expressing Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model.
    Liu KY; Shi Y; Luo P; Yu S; Chen L; Zhao Z; Mao XH; Guo G; Wu C; Zou QM
    Vaccine; 2011 Sep; 29(38):6679-85. PubMed ID: 21745524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.
    Mansouri E; Gabelsberger J; Knapp B; Hundt E; Lenz U; Hungerer KD; Gilleland HE; Staczek J; Domdey H; von Specht BU
    Infect Immun; 1999 Mar; 67(3):1461-70. PubMed ID: 10024596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
    Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
    Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous Pseudomonas aeruginosa O-antigen delivery using a Salmonella enterica serovar Typhimurium wecA mutant strain.
    Bridge DR; Whitmire JM; Makobongo MO; Merrell DS
    Int J Med Microbiol; 2016 Nov; 306(7):529-540. PubMed ID: 27476047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.
    Weimer ET; Lu H; Kock ND; Wozniak DJ; Mizel SB
    Infect Immun; 2009 Jun; 77(6):2356-66. PubMed ID: 19349426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic Escherichia coli strains.
    Lásaro MO; Luiz WB; Sbrogio-Almeida ME; Nishimura LS; Guth BE; Ferreira LC
    Infect Immun; 2004 Nov; 72(11):6480-91. PubMed ID: 15501779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa.
    Price BM; Barten Legutki J; Galloway DR; von Specht BU; Gilleland LB; Gilleland HE; Staczek J
    FEMS Immunol Med Microbiol; 2002 Jun; 33(2):89-99. PubMed ID: 12052563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.